PubRank

Harald Mischak

Author PubWeight™ 139.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human Proteinpedia enables sharing of human protein data. Nat Biotechnol 2008 4.21
2 Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006 2.29
3 Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008 2.12
4 Urine in clinical proteomics. Mol Cell Proteomics 2008 2.05
5 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010 1.90
6 Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. Cell 2004 1.79
7 Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007 1.77
8 Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 2008 1.65
9 Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 2002 1.63
10 Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005 1.63
11 Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004 1.57
12 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008 1.57
13 Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009 1.56
14 Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006 1.52
15 Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007 1.52
16 Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr Nephrol 2010 1.48
17 Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2007 1.47
18 Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet 2014 1.44
19 Urinary proteome analysis to exclude severe vesicoureteral reflux. Pediatrics 2012 1.42
20 Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009 1.41
21 Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes 2003 1.39
22 Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012 1.38
23 Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006 1.33
24 Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004 1.33
25 Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004 1.29
26 Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011 1.28
27 Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005 1.26
28 Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007 1.26
29 Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005 1.24
30 Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005 1.24
31 Urinary proteomics for prediction of preeclampsia. Hypertension 2011 1.20
32 Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem 2002 1.17
33 Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010 1.16
34 Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 2003 1.16
35 Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005 1.13
36 Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One 2013 1.12
37 Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009 1.12
38 Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 2005 1.12
39 Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010 1.12
40 Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005 1.12
41 Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2012 1.11
42 The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009 1.11
43 Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. J Biol Chem 2003 1.11
44 Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int 2010 1.10
45 Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 2010 1.09
46 Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009 1.08
47 Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 2011 1.07
48 Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2008 1.06
49 Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009 1.05
50 A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol 2003 1.03
51 Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 2009 1.02
52 Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol 2013 1.02
53 The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008 1.01
54 Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008 1.00
55 Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin Appl 2011 0.99
56 Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 2009 0.98
57 Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004 0.98
58 The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 2005 0.95
59 Induction of apoptosis by protein kinase C delta is independent of its kinase activity. J Biol Chem 2002 0.93
60 High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006 0.92
61 The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal 2009 0.92
62 Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J 2012 0.91
63 Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics 2013 0.91
64 A peptidomic approach to biomarker discovery for bovine mastitis. J Proteomics 2013 0.91
65 Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol 2009 0.90
66 Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 2005 0.90
67 Identification of urinary biomarkers by proteomics in newborns: use in obstructive nephropathy. Contrib Nephrol 2008 0.90
68 Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice. PLoS One 2013 0.90
69 A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol 2013 0.90
70 Establishment of a European Network for Urine and Kidney Proteomics. J Proteomics 2008 0.89
71 Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One 2010 0.89
72 Review on uraemic solutes II--variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 2007 0.89
73 A novel cross-talk in diacylglycerol signaling: the Rac-GAP beta2-chimaerin is negatively regulated by protein kinase Cdelta-mediated phosphorylation. J Biol Chem 2010 0.89
74 Clinical proteomics in obstetrics and neonatology. Expert Rev Proteomics 2014 0.88
75 CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013 0.88
76 Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 2006 0.88
77 Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics 2012 0.88
78 Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013 0.88
79 Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci Transl Med 2013 0.87
80 The V5 domain of protein kinase C plays a critical role in determining the isoform-specific localization, translocation, and biological function of protein kinase C-delta and -epsilon. Mol Cancer Res 2004 0.87
81 Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments. Anal Bioanal Chem 2008 0.87
82 Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol 2009 0.87
83 Mass spectrometry based proteomics in urine biomarker discovery. World J Urol 2007 0.86
84 Urinary proteomics to support diagnosis of stroke. PLoS One 2012 0.86
85 Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010 0.85
86 Value of proteomics applied to the follow-up in stem cell transplantation. Ann Hematol 2006 0.85
87 Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics 2014 0.85
88 Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One 2012 0.85
89 Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry. Proteomics Clin Appl 2007 0.85
90 Identification and analysis of phosphopeptides. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.85
91 Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol 2014 0.85
92 Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 2004 0.84
93 Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 2011 0.84
94 Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Pancreas 2016 0.84
95 Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. Electrophoresis 2005 0.84
96 Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol 2015 0.83
97 Grand rounds in proteomics at the FDA white oak, silver spring, MD, USA, april 3, 2007. Proteomics Clin Appl 2007 0.83
98 CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl 2015 0.83
99 Advances in urinary proteome analysis and applications in systems biology. Bioanalysis 2014 0.82
100 Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases. Contrib Nephrol 2008 0.82
101 Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev Clin Lab Sci 2009 0.82
102 The role of EUTox in uremic toxin research. Semin Dial 2009 0.82
103 PKC zeta enhances insulin-like growth factor 1-dependent mitogenic activity in the rat clonal beta cell line RIN 1046-38. Biochem Biophys Res Commun 2002 0.82
104 Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS One 2012 0.82
105 Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. Expert Rev Proteomics 2005 0.82
106 Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer. Proteomics Clin Appl 2013 0.81
107 Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis 2013 0.81
108 Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 2011 0.80
109 IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res 2013 0.80
110 Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients. Nephrol Dial Transplant 2002 0.80
111 Urinary proteomics in obstructive sleep apnoea and obesity. Eur J Clin Invest 2014 0.80
112 Mechanisms of arginine-vasopressin-induced Ca2+ oscillations in beta-cells (HIT-T15): a role for oscillating protein kinase C. Endocrinology 2004 0.80
113 Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol 2008 0.79
114 CE - a multifunctional application for clinical diagnosis. Electrophoresis 2007 0.79
115 Renal and urinary proteomics. Proteomics Clin Appl 2011 0.78
116 Differential polypeptide display: the search for the elusive target. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.78
117 Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. Bioanalysis 2014 0.77
118 Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. J Chromatogr A 2003 0.77
119 Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids. Methods Mol Biol 2015 0.77
120 Urinary proteomics based on capillary electrophoresis coupled to mass spectrometry in kidney disease. Methods Mol Biol 2013 0.77
121 Capillary electrophoresis coupled to mass spectrometry for proteomic profiling of human urine and biomarker discovery. Methods Mol Biol 2009 0.77
122 Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. J Urol 2012 0.77
123 Omics-bioinformatics in the context of clinical data. Methods Mol Biol 2011 0.77
124 The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates. J Mol Med (Berl) 2013 0.77
125 Application of proteomics to posttransplantational follow-up. Methods Mol Med 2007 0.76
126 Exploring the uremic toxins using proteomic technologies. Contrib Nephrol 2008 0.76
127 Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens 2011 0.76
128 Integrating proteomics profiling data sets: a network perspective. Methods Mol Biol 2015 0.76
129 Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics 2013 0.76
130 Clinical proteomics: a question of technology. Rapid Commun Mass Spectrom 2004 0.76
131 Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis 2012 0.75
132 A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS One 2011 0.75
133 Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. PLoS One 2013 0.75
134 Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 2007 0.75
135 Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers. Proteomics Clin Appl 2011 0.75
136 Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases. Curr Opin Nephrol Hypertens 2016 0.75
137 2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece. Proteomics Clin Appl 2009 0.75